Preeclampsia Screening in Denmark

​PRESIDE (Preeclampsia Screening in Denmark) is a nationwide implementation study which aims to determine performance of screening for preeclampsia in the first trimester of pregnancy in an unselected Danish population.

​A research project by Iben Riishede

Background:
Preeclampsia affects up to 8 % of pregnant women and the condition is highly associated with morbidity and mortality in both mother and child. 

Treatment with acetylsalicylic acid (ASA) during pregnancy may prevent severe preeclampsia, particularly if treatment is initiated before 16 weeks of gestation. 

Current Danish guidelines recommend prophylactic treatment with ASA to women who are considered high-risk according to information regarding previous pregnancies and diseases. This strategy identifies only 36% of cases and most women who develop early preeclampsia are not offered preventive treatment. 

Recent studies suggest that more than 80% of early preeclampsia cases can be predicted in the first trimester of pregnancy by means of screening. The screening algorithm combines maternal history with measurement of blood pressure, flow in the uterine artery and selected biochemical markers such as Pregnancy-Associated Plasma Protein A (PAPP-A) and Placental Growth Factor (PlGF).

Aim: 
To determine the performance of screening for preeclampsia in the first trimester of pregnancy in an unselected Danish population.

Responsible editor